Sunitinib belongs to the group of cancer-fighting medications known as antineoplastics and more specifically to a class of medications called tyrosine kinase inhibitors. These medications are antitumour medications that slow the growth of blood vessels that feed nutrients to cancer cells by disrupting cell communication. By slowing the growth of these blood vessels, sunitinib can help reduce the size of tumours, which is a collection of cancer cells.
